Study aims and goal: The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington’s Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance and the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
No. of study participants and sites: This phase II study aims to recruit participants from approximately 10 sites in North America.
For further information see the clinical trial registration.

*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]